Are You Aware Of Risperdal Gynecomastia Lawsuit?

Risperdal has been strongly linked causing young boys to develop female breast tissue—a condition known as gynecomastia. As a result, thousands of the victims have filed for lawsuits against manufacturer Johnson & Johnson. The medication, made by Johnson & Johnson/Janssen Pharmaceuticals, was FDA-approved for use by children and adolescents in 2006. However, it promoted the drug for young people years prior to its approval for use in children, and it lead to serious and devastating effects.

The main concern
Gynecomastia stems from a hormone imbalance and can result in the growth of male breasts and significant increase in the weight. It is has been studied by the experts how Risperdal may cause gynecomastia in some young male users because it increases levels of the hormone prolactin, which stimulates female breast development and at times even lactation.
Risperdal Inappropriate Marketing Accusations
In addition to the health side effect associated with Risperdal, Janssen, that is the manufacturing company has also been blamed of using improper marketing techniques to promote the medication. Lawsuits claim the drug was released and marketed for unapproved uses in children and adults, including for the treatment of chemical restraint, ADHD, and schizoaffective disorder. It should be noted here that although it is illegal for drug manufacturers to promote or market a drug off-label, unapproved uses, it is legal for doctors to prescribe medications for the same.
Hundreds of Risperdal lawsuit have been filled by affected patients demanding compensation for their financial damage. Furthermore, they have also stated how the patients have been victimized for the physical condition and its undesired manifestations. Gynecomastia leaves a lifelong emotional scar. Corrective surgeries such as double mastectomies might at times mandatory to cure such situations.


In 2005, several years after Risperdal problems spread into the public, U.S. Food and Drug Administration asked Janssen to add a black box warning to Risperdal.
The black box statement was added as a result of reports that older patients treated for dementia with atypical antipsychotics had a higher risk of death when compared to patients in a placebo control group.
If you know someone who suffered from similar complications, ask them to visit Risperdal411.com or dial 855-576-4392.

Comments

Popular posts from this blog

Understanding The Side Effects Of Risperdal

Major And Minor Effects Of Risperdal